Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 15, 2016

View Archived Issues

Shanghai Institute Materia Medica develops tyrosine kinase inhibitors

ExpreS2ion and Abivax enter collaboration on Ebola prophylaxis and treatment program

Medicenna Biopharma begins phase II study of MDNA-55

European Commission grants conditional approval to Ocaliva

KemPharm reports positive results from phase I proof-of-concept study of d-MPH prodrug

ALS symptoms deteriorate after stopping ibudilast treatment in clinical trial

AN-13762 described as representing a new class of antimalarial

Novel therapeutic targets described at the Society for Neuroscience Annual Meeting

Concert Pharmaceuticals completes phase I study of JAK inhibitor for alopecia areata

TPC-064: a novel mutant-selective EGFR inhibitor

vTv Therapeutics reports topline data from phase II trial of TTP-273 in type 2 diabetes

Kiadis obtains U.K. approvals for phase I/II trial of ATIR-201 for thalassemia

FDA gives orphan drug designation to nintedanib in mesothelioma

Encouraging results reported from tolerability proof-of-concept study of KarXT

Epigenetic compound CTI-309 shows promise as Alzheimer's disease candidate

TSRI, Icahn School of Medicine and UPenn patent nAChR modulators

Bicycle Therapeutics collaborates with Cancer Research UK to study BT-1718

Harvard and Evotec divulge novel bacterial glycosyl transferase inhibitors

Merck & Co. discovers soluble guanylate cyclase activators

FDA approves Eucrisa for atopic dermatitis

Principia Biopharma patents new FGFR inhibitors

Chong Kun Dang Holdings divulges new histone deacetylase inhibitors

Hologic to divest blood screening business to Grifols

argenx initiates phase I/II study of ARGX-110 with azacitidine in newly diagnosed AML

Third Rock Ventures launches Goldfinch Bio with a focus on therapies for kidney disease

Biogen files for Japanese approval of nusinersen for SMA

Lonza set to acquire Capsugel

CM-4620 receives EMA orphan designation for acute pancreatitis

Gamunex-C granted FDA orphan status for myasthenia gravis

Polatuzumab vedotin given U.S. orphan drug designation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...